77 related articles for article (PubMed ID: 15349004)
1. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder.
Rickels K; Mangano R; Khan A
J Clin Psychopharmacol; 2004 Oct; 24(5):488-96. PubMed ID: 15349004
[TBL] [Abstract][Full Text] [Related]
2. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder.
Book SW; Thomas SE; Randall PK; Randall CL
J Anxiety Disord; 2008; 22(2):310-8. PubMed ID: 17448631
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder.
Knijnik DZ; Blanco C; Salum GA; Moraes CU; Mombach C; Almeida E; Pereira M; Strapasson A; Manfro GG; Eizirik CL
Eur Psychiatry; 2008 Dec; 23(8):567-74. PubMed ID: 18774274
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled trial of venlafaxine to treat behavioural disorders in cats: a pilot study.
Metz D; Medam T; Masson S
J Feline Med Surg; 2022 Jun; 24(6):539-549. PubMed ID: 34420375
[TBL] [Abstract][Full Text] [Related]
5. Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social Anxiety.
Shadli SM; Kawe T; Martin D; McNaughton N; Neehoff S; Glue P
Int J Neuropsychopharmacol; 2018 Aug; 21(8):717-724. PubMed ID: 29718262
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of venlafaxine hydrochloride combined with tandospirone citrate for patients with vascular depression accompanied by somatic symptoms: An open-labeled randomized control trial.
Chen H; Lin Y; Zhao Z; Lin T; Lin Q; Chen X; Wu W; Zeng G; Wu S; Liu N; Chen H; Chen R; Xiao Y
CNS Neurosci Ther; 2024 Mar; 30(3):e14650. PubMed ID: 38514905
[TBL] [Abstract][Full Text] [Related]
7. Emotional and interpersonal mechanisms in community SSRI treatment of social anxiety disorder.
Rappaport LM; Hunter MD; Russell JJ; Pinard G; Bleau P; Moskowitz DS
J Psychiatry Neurosci; 2021 Jan; 46(1):E56-E64. PubMed ID: 33026311
[TBL] [Abstract][Full Text] [Related]
8. Predictors of response to an attention modification program in generalized social phobia.
Amir N; Taylor CT; Donohue MC
J Consult Clin Psychol; 2011 Aug; 79(4):533-41. PubMed ID: 21707134
[TBL] [Abstract][Full Text] [Related]
9. Exploring venlafaxine effects on chronic vulvar pain: Changes in mood and pain regulation networks.
Awad-Igbaria Y; Abu-Ata S; Nakhleh-Francis Y; Lowenstein L; Ginat K; Bornstein J; Palzur E; Shamir A
Neuropharmacology; 2024 Feb; 243():109788. PubMed ID: 37984764
[TBL] [Abstract][Full Text] [Related]
10. Long-term administration of escitalopram in patients with social anxiety disorder in Japan.
Asakura S; Hayano T; Hagino A; Koyama T
Neuropsychiatr Dis Treat; 2016; 12():1817-25. PubMed ID: 27524899
[TBL] [Abstract][Full Text] [Related]
11. Disability in patients consulting for anxiety or mood disorders in primary care: response to antidepressant treatment.
Gérard A; Liard F; Crochard A; Goni S; Millet B
Neuropsychiatr Dis Treat; 2012; 8():605-14. PubMed ID: 23271910
[TBL] [Abstract][Full Text] [Related]
12. Instruments for the assessment of social anxiety disorder: Validation studies.
Osório Fde L; Crippa JA; Loureiro SR
World J Psychiatry; 2012 Oct; 2(5):83-5. PubMed ID: 24175172
[TBL] [Abstract][Full Text] [Related]
13. Corrigendum to "Clinical efficacy of Shugan granule in the treatment of mixed anxiety-depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial" [J. Ethnopharmacol. 290 (2022) 115032].
Li Y; Li L; Guo R; Yu H; Wang X; Wang B; Wang Q; Li Z; Zhao H; Temu Q; Chen X; Zhang Y; An J; Cai X; Li A; Qi L; Shang J; He H; Yang D; Lin J; Zhang Y; Zou T
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117370. PubMed ID: 37923593
[No Abstract] [Full Text] [Related]
14. Time course of effects of venlafaxine on migraine and generalized pruritus in a patient with depression.
Miyahara Y; Funahashi H; Haruta-Tsukamoto A; Hidaka H; Fujimoto T; Horinouchi A; Nishimori T; Ishida Y
Clin Case Rep; 2021 Nov; 9(11):e05088. PubMed ID: 34815877
[TBL] [Abstract][Full Text] [Related]
15. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.
Liebowitz MR; Gelenberg AJ; Munjack D
Arch Gen Psychiatry; 2005 Feb; 62(2):190-8. PubMed ID: 15699296
[TBL] [Abstract][Full Text] [Related]
16. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study.
Schutters SI; Van Megen HJ; Van Veen JF; Denys DA; Westenberg HG
Int Clin Psychopharmacol; 2010 Sep; 25(5):302-4. PubMed ID: 20715300
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.
Pollack M; Mangano R; Entsuah R; Tzanis E; Simon NM; Zhang Y
Psychopharmacology (Berl); 2007 Oct; 194(2):233-42. PubMed ID: 17589833
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.
Liebowitz MR; Mangano RM; Bradwejn J; Asnis G;
J Clin Psychiatry; 2005 Feb; 66(2):238-47. PubMed ID: 15705011
[TBL] [Abstract][Full Text] [Related]
19. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
Brawman-Mintzer O; Knapp RG; Rynn M; Carter RE; Rickels K
J Clin Psychiatry; 2006 Jun; 67(6):874-81. PubMed ID: 16848646
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
